AIFA makes clear notes on drugs: “it is unacceptable that bureaucracy hinders access to innovative drugs”

On the topic of drugs, Nisticò (Aifa) launches criticism without half measures: “It is unacceptable that bureaucracy hinders access to innovative people”.

At the center of the attention of the president of the Italian Medicines Agency (Aifa), Robert Nisticò, is a question of fundamental importance: guaranteeing fair and rapid access to innovative medicines. During the 29th Congress of the Federation of hospital internal medicine doctors (Fadoi) held in Rimini, Nisticò underlined the urgency of opening technical tables with scientific societies to address and resolve disparities in access to pharmacological treatments between patients in the different regions Italian. The current situation, which sees patients from Calabria and northern Italy in conditions of different accessibility to treatments, has been defined as unacceptable.

One of the obstacles most highlighted by Nisticò concerns the long bureaucratic processes that prevent the immediate availability of innovative therapies for patients. With procedures that continue for years, the AIFA president has highlighted the need for a more flexible and rapid system that not only allows immediate access to new post-authorization therapies but also guarantees continuous monitoring of the risk-to-risk ratio. benefit of drugs.

Bureaucracy as an obstacle

Financial sustainability represents another crucial issue addressed by Nisticò. Although it is essential to ensure the sustainability of the national healthcare system, this must not become a impediment to the introduction of therapeutic innovations. The president proposes a strategy based on immediate negotiation with the pharmaceutical industries at the time of authorization of new medicines, possibly providing for subsequent economic adjustments based on the actual results of the therapies.

The appeal launched by Robert Nisticò aims to promote a profound reflection on ways in which the Italian healthcare system manages the introduction of innovative medicines. The goal is to overcome bureaucratic and financial obstacles through pragmatic solutions that take into account both the need to guarantee effective and equally distributed care among all Italian citizens, and economic sustainability for the state coffers.

In conclusion, the message brought forward by the president of AIFA at the FADOI Congress lays the foundations for a constructive dialogue between all the actors involved in the healthcare sector. Only through collaboration between healthcare institutions, scientific societies and pharmaceutical industries will it be possible to achieve the common objective of making innovative therapies available without major delays to patients who need them, thus overcoming one of the greatest current limitations in the field of Italian public health .